Evidence map›Paper›PMID 39690250›Full record

ArticleAnnals of hematology2025

Prophylactic trimethoprim-sulfamethoxazole is safe in adult patients with primary central nervous system lymphoma receiving high-dose methotrexate.

Qinxia Xu, Ziran Li, Tianling Ding, Xiaoyan Qiu, Zhuo Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qinxia XuDepartment of Pharmacy, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Ziran LiDepartment of Pharmacy, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai, 200040, China.
Tianling DingDepartment of Hematology, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai, 200040, China.
Xiaoyan QiuDepartment of Pharmacy, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai, 200040, China.
Zhuo WuDepartment of Pharmacy, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai, 200040, China. zwu14@fudan.edu.cn.

Funding

Clinical Pharmacy Research Fund Project of the Clinical Pharmacy Branch of the Chinese Medical Association of the China International Medical Exchange Foundation Z-2021-46-2101-2023National Natural Science Foundation of China 82003863Shanghai Municipal Health Commission Special Project for Clinical Research in the Health Care Industry 202040424Shanghai Municipal Health Commission Special Project for Clinical Research in the Health Care Industry 20234Y0818Shanghai "Rising Stars of Medical Talent" Youth Development Program Clinical Pharmacist Program SHWRS (2021) _099
6 · The paper itself

Abstract

This retrospective study investigated the potential drug-drug interactions between trimethoprim-sulfamethoxazole (TMP-SMZ) and high-dose methotrexate (HD-MTX) in adult patients with primary central nervous system lymphoma (PCNSL). A total of 143 Chinese adult patients with PCNSL who received 498 cycles of MTX were included. Differences in the pharmacokinetics of MTX, including C

Indexed as

Antimetabolites, AntineoplasticCentral Nervous System NeoplasmsLymphomaMethotrexateTrimethoprim, Sulfamethoxazole Drug CombinationAcute Kidney InjuryAdultAgedDrug InteractionsFemaleHumansMaleMiddle AgedRetrospective StudiesAntimetabolites, AntineoplasticMethotrexateTrimethoprim, Sulfamethoxazole Drug CombinationAdverse drug reactionsMethotrexatePharmacokineticsPrimary central nervous system lymphomaTrimethoprim-sulfamethoxazole

Identifiers

PMID39690250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.